Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411181 | 0.95 | SLC6A3 (0.58) | HTTSGMS2SLC6A3KMT2ALMNA | |
| SCHEMBL4002825 | 0.90 | FFAR4 (0.55) | HTTSGMS2NPC1SLC6A3LMNA | |
| SCHEMBL5309541 | 0.89 | KMT2A (0.64) | NPC1SLC6A3MEN1KMT2ALMNA | |
| SCHEMBL13044291 | 0.89 | SGMS2 (0.55) | HTTSGMS2GAASLC6A3MEN1 | |
| SCHEMBL1097551 | 0.88 | SGMS2 (0.54) | HTTSGMS2NPC1GAAPTGER1 | |
| SCHEMBL29930977 | 0.88 | SGMS2 (0.54) | HTTSGMS2NPC1GAAPTGER1 | |
| SCHEMBL25720776 | 0.88 | MAPT (0.63) | HTTSGMS2NPC1GAAPTGER1 | |
| SCHEMBL1346892 | 0.88 | ALDH1A1 (0.56) | HTTSGMS2KMT2ALMNAMAPT | |
| SCHEMBL1305662 | 0.88 | HPGD (0.57) | HTTSGMS2NPC1GAAPTGER1 | |
| SCHEMBL5940976 | 0.88 | SGMS2 (0.54) | HTTSGMS2NPC1GAAPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3678203-B1 | METHOD FOR PREPARING ORGANIC ELECTRONIC DEVICE | LG CHEMICAL LTD (KR) | 2025-06-18 | — | — | EP | disclosed |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12202997-B2 | Encapsulating composition | LG CHEM, LTD. (KR) | 2025-01-21 | — | — | US | disclosed |
| EP-3683854-B1 | METHOD FOR ENCAPSULATING ORGANIC ELECTRONIC ELEMENT | LG CHEMICAL LTD (KR) | 2024-11-27 | — | — | EP | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12104075-B2 | Encapsulating composition | LG CHEM, LTD. (KR) | 2024-10-01 | — | — | US | disclosed |
| US-12097629-B2 | Razor cartridge | BIC Violex Single Member S.A. (GR) | 2024-09-24 | — | — | US | disclosed |
| US-12096648-B2 | Method for encapsulating organic electronic element | LG CHEM, LTD. (KR) | 2024-09-17 | — | — | US | disclosed |
| EP-3800228-B1 | SEALANT COMPOSITION | LG CHEMICAL LTD (KR) | 2024-07-31 | — | — | EP | disclosed |
| US-12030988-B2 | Encapsulating composition | LG CHEM, LTD. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-4267187-A | AS PHARMACEUTICALS IN TREATING CARDIOVASCULAR DISSORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4240964-A | PHARMACOLOGICAL CHEMICAL INTERMEDIATE FORM BY CYCLIZING REACTION PRODUCT OF O-BENZYLOXYBENZOIC ACID ALLYLAMIDE AND PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | disclosed |
| US-4148900-A | ANTIALLERGIC | CARLO ERBA S.P.A. (IT) | 1979-04-10 | — | — | US | disclosed |
| US-4115567-A | TREATMENT OF ALLERGIES | CARLO ERBA S. P. A. (IT) | 1978-09-19 | — | — | US | disclosed |
| US-4104274-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4083953-A | ANTIALLERGENS | CARLO ERBA, S.P.A. (IT) | 1978-04-11 | — | — | US | disclosed |
| US-4076720-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4065467-A | ANTIALLERGENS, ANTIULCER AGENTS, TREATMENT OF RESPIRATORY SYSTEM AND PULMONARY DISORDERS | CARLO ERBA, S. P. A. (IT) | 1977-12-27 | — | — | US | disclosed |
| US-4056619-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1977-11-01 | — | — | US | disclosed |
| US-3998974-A | Comestibles containing non-nutritive flavoring | DYNAPOL CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | HTT 4784/4885SGMS2 73/4885NPC1 2991/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | HTT 4784/4885SGMS2 73/4885NPC1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.